Elicio Therapeutics Inc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $0TTM through 30 Jun 2026
Net Income -$37.8MTTM through 30 Jun 2026
Free Cash Flow -$37.7MTTM through 30 Jun 2026
Margins
| Current |
|---|
Returns
-152.9%ROA
Balance Sheet Health
Debt / Equity5.75x
Current Ratio2.38x
Net Debt-$18.6Mnet cash position
Cash & Equivalents$23.5M
Quality Metrics
Altman Z-Score-13.45
Piotroski F-Score4 / 9
Earnings-Beat Rate25.0%
Multi-Year Trend
RevenueFY2022: $2.3M
Diluted EPS-$2.15TTMFY2025: $-2.58
Dividend
No dividend
Capital Allocation
R&D Spend$23.7M
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| Immunotherapy Development | $0 | View detailsThe company reported Phase 2 AMPLIFY-7P trial results in June 2026, which fell short of its pre-specified primary disease-free survival endpoint in the intent-to-treat population. |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.